|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | ||
| Finance income | ||
| PIPE issuance expenses | ||
| Share based payment | ||
| Interest on convertible loans | ||
| Fair value revaluation of investment in shares | ||
| Fair value revaluation of derivative warrant liability | ||
| Fair value revaluation in convertible notes | ||
| Change in: | ||
| Other current assets | ||
| Employees and payroll-related liabilities | ||
| Other payables and accrued expenses | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Proceeds from sale of investment in shares | ||
| Investment in shares and warrants | ||
| Investment in Short Term deposit | ||
| Investment in Long Term deposit | ||
| Purchase of property and equipment | ||
| Net cash provided by (used in) investing activities | ||
| Cash flows from financing activities | ||
| Proceeds from issuance of convertible loan | ||
| Issuance of ordinary shares and warrants under initial public offering | ||
| Repayment of a convertible loan | ||
| Net cash provided by financing activities | ||
| Change in cash and cash equivalents | ||
| Cash and cash equivalents at the beginning of the year | ||
| Cash and cash equivalents at the end of the year | ||
| Non-cash financing activities: | ||
| Exercise of warrants into ordinary shares | ||
| IPO warrants exchange | ||
| Issuance of ordinary shares in exchange for patent license (see Note 8a6) | ||
| Conversion of convertible notes into ordinary shares (see Note 11) | ||
| Reclassification of warrant liability to equity (see Note 10) | ||
| Conversion of preferred shares into ordinary shares (see note 7) |
Loading...
